Evidence map›Paper›PMID 28194742›Full record

Observational studyJournal of echocardiography2017

Predictability of tricuspid annular plane systolic excursion for the effectiveness of tolvaptan in patients with heart failure.

Toru Niwa, Katsuhisa Waseda, Tomofumi Mizuno, Yusuke Nakano, Kentaro Mukai, Hirokazu Wakabayashi, Atsushi Watanabe, Hirohiko Ando, Hiroaki Takashima, Tetsuya Amano

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of echocardiography, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Toru NiwaDepartment of Cardiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Japan.
Katsuhisa WasedaDepartment of Cardiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Japan.
Tomofumi MizunoDepartment of Cardiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Japan. tomofumi@aichi-med-u.ac.jp.
Yusuke NakanoDepartment of Cardiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Japan.
Kentaro MukaiDepartment of Cardiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Japan.
Hirokazu WakabayashiDepartment of Cardiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Japan.
Atsushi WatanabeDepartment of Cardiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Japan.
Hirohiko AndoDepartment of Cardiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Japan.
Hiroaki TakashimaDepartment of Cardiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Japan.
Tetsuya AmanoDepartment of Cardiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Japan.
Aichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is no echocardiographic predictor of the effectiveness of tolvaptan in patients with heart failure (HF). The aim of this study was to investigate the echocardiographic predictor of responders to tolvaptan in patients with HF.

methodsThis observational study consisted of 62 consecutive in-hospital patients with HF who received tolvaptan with volume overload despite standard therapies. The echocardiography data were obtained within 1 week before the administration of tolvaptan. Tolvaptan responders were defined as those having a body weight decrease from baseline >1 kg on the morning of day 8.

resultsThe mean age of the 62 patients was 75.1 ± 13.9 years, and 45 patients (72.6%) were considered to be responders. Tricuspid annular plane systolic excursion (TAPSE) was significantly higher (17.1 ± 3.8 vs. 13.0 ± 3.9 mm; p = 0.0004) and the tricuspid valve regurgitation pressure gradient (33.3 ± 14.6 vs. 44.9 ± 12.2 mmHg; p = 0.007) and estimated right atrium pressure (7.8 ± 4.2 vs. 10.3 ± 4.5 mmHg; p = 0.043) were significantly lower in the Responder group than in the Non-responder group. In a multivariate logistic regression analysis, TAPSE was found to be an independent predictor of response (odds ratio 1.28; 95% confidence interval 1.03-1.60). According to the receiver operating characteristics analysis, the area under the curve of TAPSE was the largest among the parameters measured by echocardiography. The cut-off value for TAPSE to predict responders was determined to be 17.0 mm (sensitivity = 56.8%, specificity = 94.1%).

conclusionsTAPSE is a simple predictor of the effectiveness of tolvaptan in patients with HF.

Indexed as

AgedAged, 80 and overAntidiuretic Hormone Receptor AntagonistsBenzazepinesEchocardiographyFemaleHeart FailureHumansMaleMiddle AgedPrognosisROC CurveSystoleTolvaptanTricuspid ValveTricuspid Valve InsufficiencyAntidiuretic Hormone Receptor AntagonistsBenzazepinesTolvaptanEchocardiographyEffectiveness of tolvaptanRight ventricle dysfunctionTAPSE

Identifiers

PMID28194742
OpenAlexW2588801804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.